Floatz logo

Anti-Cd30/Cd16A Monoclonal Antibody Afm13

Mycosis Fungoides

M.D. Anderson Cancer Centermonoclonal_antibodyPhase 2Dormant
BB
69/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
95/ 100

Competitive context

51 Active assets in the Mycosis Fungoides cohort.

Asset / SponsorPhaseRating
(+)-VINCRISTINE
Virogen Biotechnology Inc.
Phase 4BBB
Cyclophosphamide
National Cancer Institute (NCI)
Phase 4BBB
Fludarabine
National Cancer Institute (NCI)
Phase 2BBB
FILGRASTIM
Mayo Clinic
Phase 4BBB
METHOTREXATE
Polish Lymphoma Research Group
Phase 4BBB

View all 50 →

Same molecule, other indications

Anti-Cd30/Cd16A Monoclonal Antibody Afm13 is also rated in:

peripheral T-cell lymphoma, not otherwise specifiedDormant
B
Indicative ·
61 / 100
View asset →
Hodgkins lymphomaDormant
CCC
Indicative ·
55 / 100
View asset →
primary cutaneous T-cell non-Hodgkin lymphomaDormant
CCC
Indicative ·
52 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →